SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:

Citi's 2024 Global Healthcare Conference, including a panel discussion at 2:30 PM ET on Tuesday, December 3, 2024 in Miami, Florida; and

Piper Sandler's 36th Annual Healthcare Conference, including a panel discussion at 3:00 PM ET and a fireside chat at 4:00 PM ET on Wednesday, December 4, 2024 in New York, New York.

kAmp =:G6 H6342DE[ :7 C64@C565[ @7 6249 AC6D6?E2E:@? 42? 36 2446DD65 F?56C "tG6?ED U2>Aj !C6D6?E2E:@?D" :? E96 x?G6DE@CD D64E:@? @7 E96 r@>A2?J'D H63D:E6 2E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lr';FrvBB3dGAz2%*<=x:~{8vEsb#sJ}y:*zC*F}&sJ!;}0w\gJ'C~(d(5_;I~cu;F4p6fC|Jutc#JAp6ztc'~(c;hJ7}pCG6''3twzspgw=hh?u~G:>gyCb>;d:w0*#*"'{}8=6Fha{hvp?D45B@9_Csvc*tteE24Cd_8C3#!sv6+r42yqa:G#G"f5g=7e;D{0cAeac}HJ'fagBcpF;#)=CI)%%|:9c}4:y{<>>46%(d}g'd>zsDs4BfJ==e2b?&>aGJ276fKBBDHc{<v6|}c$J7u3}Ixd4<9\pc!g)>Fu:CagKKgFF8q%|Fcax:Jd4'}C6?%Iv_:D(36ChtyG|':Kw#~'H9$y<3aauf;!@'6dz|>H:5p)'8x)9'K}D0v437arx>zs~{6rCFJy7z\Dzu0aG'g$@@Be:xrb8z(|@A{6Df7wd)@a&FvedDI|J|H!<tdh~:Je%$q!u@<"#rJ&_a_fD!5g*g%?!wH8f7*w2)hr2p'b6cvx699#'zx~zww=sp$_='Iv:HB@67I&>:$@|_6rq\G@aA&''pt2c8*h#E8{9(2dbAd=yH~$&?hp$tB:yBQ C6=lQ?@7@==@HQmHHH]72E6E96C2A6FE:4D]4@>k^2m] %96 2C49:G65 H6342DE H:== 36 2G2:=23=6 @? E96 r@>A2?J'D H63D:E6 D9@CE=J 27E6C E96 6G6?E]k^Am

kAmp3@FE u2E6 %96C2A6FE:4D[ x?4]k^Am

kAmu2E6 %96C2A6FE:4D :D 2 4=:?:42=\DE286 3:@A92C>246FE:42= 4@>A2?J 565:42E65 E@ 3C:?8:?8 2 7:CDE\:?\4=2DD A:A6=:?6 @7 :?5F465 A=FC:A@E6?E DE6> 46== W:!$rX\56C:G65 46==F=2C :>>F?@E96C2A:6D E@ A2E:6?ED H:E9 42?46C 2?5 2FE@:>>F?6 5:D62D6D] &D:?8 :ED AC@AC:6E2CJ :!$r AC@5F4E A=2E7@C>[ E96 r@>A2?J 92D 6DE23=:D965 2 =6256CD9:A A@D:E:@? :? 4C62E:?8 >F=E:A=6I65\6?8:?66C65 >2DE6C :!$r =:?6D 2?5 :? E96 >2?F724EFC6 2?5 4=:?:42= 56G6=@A>6?E @7 @77\E96\D96=7[ :!$r\56C:G65 46== AC@5F4ED] %96 r@>A2?J'D A:A6=:?6 :?4=F56D :!$r\56C:G65 ?2EFC2= <:==6C W}zX 46== 2?5 %\46== AC@5F4E 42?5:52E6D[ H9:49 2C6 D6=64E:G6=J 56D:8?65[ :?4@CA@C2E6 ?@G6= DJ?E96E:4 4@?EC@=D @7 46== 7F?4E:@?[ 2?5 2C6 :?E6?565 E@ 56=:G6C >F=E:A=6 E96C2A6FE:4 >6492?:D>D E@ A2E:6?ED] u2E6 %96C2A6FE:4D :D 9625BF2CE6C65 :? $2? s:68@[ rp] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lr';FrvBB3dGAz2%*<=x:~{8vEsb#sJ}y:*zC*F}&sJ||'f(<"Ht"+z#!}zBvdD>%a*vIvuw'x?<f|'3_v:)E|f+r9F=c#yI'Awy&y+5v_**lQ C6=lQ?@7@==@HQmHHH]72E6E96C2A6FE:4D]4@>k^2m]k^Am

kAmr@?E24Eik^Am

kAmr9C:DE:?2 %2CE28=:2k^Am

kAm!C64:D:@? p"k^Am

kAma'a]bea]'a__k^Am

kAmk2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l3G9vaI3G{!Ab!}7{#h"*%_{+}!2bx%;J"2w}&c'&|37)phI}#Fw7hD_$$4*G4wD3'A8\ga~0J@<?0+A0\D6|fc=$csH:ez}"g0+d"K+"#x_&!<DqpI_t>;0B!48e7K2t9@9=FD>:@Jxb)d(xrzw;f8llQ C6=lQ?@7@==@HQm49C:DE:?2]E2CE28=:2oAC64:D:@?2B]4@>k^2mk^Am

kAmk^Am

kAmk^Am